Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency

Neurology

Prevalence

0.1 / 100K

0 drugs in development·0 companies·1 clinical trial

Frequently asked questions

How many clinical trials target Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency?

There are 1 clinical trial targeting Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency tracked by BioSniper.

What is the prevalence of Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency?

The estimated prevalence of Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency is approximately 0.1 per 100,000 population.

Deep-dive into Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency — Drugs in Development & Clinical Trials | BioSniper